PD173955 (Standard)
PD173955 (Standard) is the analytical standard of PD173955 (HY-10395). This product is intended for research and analytical applications. PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity.
For research use only. We do not sell to patients.
- CAS No.: 260415-63-2
- Formula: C21H16Cl2N4OS
- Molecular Weight:443.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 260415-63-2
-
Molecular Weight 443.35
-
Formula C21H16Cl2N4OS
-
SMILES
O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Moasser MM, et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59(24):6145-52. PMID: 10626805. [Content Brief]
[2]. Martinelli G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005 Nov;19(11):1872-9. [Content Brief]
[3]. Netzer WJ, et al. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1389-1394. [Content Brief]
[4]. Wolff NC, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105(10):3995-4003. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)